ESC 365 - Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial

ESC Professional Premium Access

Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial

Session: Late-Breaking Science - Innovations in drug treatment

Topic: Pharmacotherapy

Speaker: Doctor B. Ingraham (Rochester, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Brenden Ingraham

Mayo Clinic Hospital-Rochester, Rochester (United States of America)

1 presentation

0 follower

3 more presentations in this session

Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Lifetime prediction and Treatment Benefit in HFrEF (LIFE-HF).

Speaker: Doctor S. Koudstaal (Gouda, NL)

ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.

Speaker: Professor D. Bhatt (New York, US)

Access the full session

Late-Breaking Science - Innovations in drug treatment

Speakers: Doctor B. Ingraham, Professor F. Zannad, Doctor S. Koudstaal, Professor D. Bhatt

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources